MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
4.020
-0.150 (-3.60%)
Feb 18, 2025, 4:00 PM EST - Market closed
MaxCyte Revenue
MaxCyte had revenue of $8.16M in the quarter ending September 30, 2024, with 2.00% growth. This brings the company's revenue in the last twelve months to $45.60M, up 19.85% year-over-year. In the year 2023, MaxCyte had annual revenue of $41.29M, down -6.72%.
Revenue (ttm)
$45.60M
Revenue Growth
+19.85%
P/S Ratio
n/a
Revenue / Employee
$318,874
Employees
143
Market Cap
437.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
Dec 31, 2019 | 21.62M | 4.95M | 29.72% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MXCT News
- 6 days ago - MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - GlobeNewsWire
- 11 days ago - MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - GlobeNewsWire
- 19 days ago - Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire
- 19 days ago - MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - GlobeNewsWire
- 5 weeks ago - MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - MaxCyte Announces Retirement of Board Member Art Mandell - GlobeNewsWire
- 2 months ago - MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance - GlobeNewsWire
- 3 months ago - MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - GlobeNewsWire